Status:
UNKNOWN
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Lead Sponsor:
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborating Sponsors:
Jingzhou Central Hospital
Conditions:
Colorectal Cancer
Neoplasms
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
Detailed Description
60 patients with stageⅠ\~ Ⅲ CRC, who had received surgery and kept their tumor tissue, will be randomly divided into group A (receive DC-CIK treatment, chemotherapy and radiotherapy) or group B (just ...
Eligibility Criteria
Inclusion
- 18\~80 years old;
- Histologically confirmed with colorectal cancer at stage Ⅰ\~Ⅲ;
- Patients who can accept curative operations;
- Patients who have a life expectancy of at least 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.
Exclusion
- Hemoglobin\<8.0 g/dL,Platelet count \<75 x 10\^9/L; ALT, AST, BUN and Cr more than normal limits on 3.0 times ;
- Known or suspected allergy to the investigational agent or any agent given in association with this trial;
- Pregnant or lactating patients;
- Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection;
- Patients who are suffering from serious autoimmune disease;
- History of organ allograft;
- Patients who had distant metastases;
- Patients who had active infection;
- Prior use of any anti-cancer treatment in 30 days;
- Now or recently will join another experimental clinical study ;
- Other situations that the researchers considered unsuitable for this study.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02202928
Start Date
July 1 2014
End Date
December 1 2017
Last Update
December 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jingzhou Central Hospital Immunotherapy center
Jingzhou, Hubei, China, 434020